Finance
Lilly Seals up to $7.8 Billion Deal for Centessa in Sleep Disorder Bet
Published by Global Banking & Finance Review®
Posted on March 31, 2026
3 min readLast updated: March 31, 2026
Add as preferred source on GoogleQuick Summary
Eli Lilly will acquire Centessa Pharmaceuticals for up to $7.8 billion to gain a promising orexin‑2 receptor agonist pipeline targeting sleep disorders, notably cleminorexton for narcolepsy and idiopathic hypersomnia.
Lilly Buys Centessa in $7.8B Bet on Sleep Disorder Drug Market Expansion
Eli Lilly's Strategic Acquisition of Centessa Pharmaceuticals
By Sneha S K
March 31 (Reuters) - Eli Lilly said on Tuesday it would buy Centessa Pharmaceuticals in a deal valued at up to $7.8 billion as the U.S. drugmaker looks to diversify beyond its metabolic portfolio and expand into treatments for sleep disorders.
Centessa's Orexin-Targeting Drug Pipeline
UK-based Centessa is developing a new class of treatments designed to target orexin, a molecule in the brain that regulates the sleep-wake cycle. Its lead drug, cleminorexton, is in mid-stage studies for narcolepsy and idiopathic hypersomnia, disorders that cause excessive daytime sleepiness.
Market Potential for Sleep Disorder Treatments
Sales of narcolepsy drugs are currently worth about $2.5 billion and can significantly expand following the entry of orexin agonists, Oppenheimer analyst Kostas Biliouris said in a note.
About 50 million to 70 million Americans have a sleep disorder, according to the U.S. National Institutes of Health.
Deal Details and Financial Terms
Lilly has offered $38 per share in cash, a premium of 37.8% to the last close of Centessa's U.S.-listed stock. Its
U.S.-listed shares jumped 45% in morning trading. Shares of Lilly were up 3.1% at $914.29.
The U.S. company has also offered one non-transferable contingent value right (CVR) of about $9 per share, or worth about $1.5 billion.
The deal is expected to close in the third quarter.
Big Pharma Awakens to New Opportunity
Lilly's Recent Acquisition Strategy
This marks Lilly's biggest deal since its buyout of Loxo Oncology for about $8 billion in 2019.
Eli Lilly, which hit a trillion-dollar valuation last year on the blockbuster success of its weight-loss treatments, has been ramping up investments to strengthen other parts of its pipeline.
Other Notable Acquisitions
This year, it snapped up Orna Therapeutics for $2.4 billion to expand its next-generation cell therapy capabilities, and paid more than $1 billion to buy autoimmune drug developer Ventyx Biosciences.
Industry Reactions and Competitive Landscape
Still, several analysts said the premium was modest and left the door open for rival bids, given Centessa's promising pipeline.
"Johnson & Johnson has also recently expressed desire to expand its neuroscience franchise and could make sense as rival bidder," Biliouris said.
Other companies developing drugs that target orexin include Alkermes and Takeda.
Lilly's deal is favorable for Alkermes, said RBC Capital Markets analyst Leonid Timashev, as it highlights large pharma interest in the sleep space and underscores what could be a large indication.
It would not be surprising if Alkermes could be a takeout target as well, he said.
(Reporting by Sneha S K in Bengaluru; Additional reporting by Puyaan Singh; Editing by Sriraj Kalluvila)
Key Takeaways
- •Lilly gains Centessa’s mid‑stage orexin‑2 receptor agonist pipeline, including cleminorexton, to expand into sleep‑wake disorder therapeutics—part of its neuroscience diversification strategy (prnewswire.com)
- •The narcolepsy and hypersomnia market—currently around $2.5 billion in the U.S. and expected to grow rapidly as orexin agonists gain FDA/EMA approvals—offers substantial commercial potential (delveinsight.com)
- •This deal represents Lilly’s largest since its 2019 $8 billion acquisition of Loxo Oncology and follows other major buys like Orna and Ventyx this year, underlining its aggressive expansion beyond metabolic drugs (en.wikipedia.org)
References
Frequently Asked Questions about Lilly seals up to $7.8 billion deal for Centessa in sleep disorder bet
1What is the value of Lilly's deal to acquire Centessa?
The deal is valued at up to $7.8 billion, including a $38-per-share cash offer and a contingent value right.
2What sleep disorders is Centessa's lead drug targeting?
Centessa's lead drug, cleminorexton, is in mid-stage studies for narcolepsy and idiopathic hypersomnia.
3How does the acquisition help Lilly's business?
The acquisition expands Lilly's drug portfolio beyond metabolic treatments into promising sleep disorder therapies.
4When is the Lilly-Centessa deal expected to close?
The transaction is expected to close in the third quarter of the year.
5What is the current market size for narcolepsy drugs?
Sales of narcolepsy drugs are currently worth about $2.5 billion, with potential for expansion.
